The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
True recurrence vs. new primary ipsilateral breast tumor relapse: An analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management
Open accessAbstract
PURPOSE: The purpose of this study was to classify all ipsilateral breast tumor relapses (IBTR) in patients treated with conservative surgery and radiation therapy (CS+RT) as either new primary tumors (NP) or true local recurrences (TR) and to assess the prognostic and therapeutic implications of this classification. METHODS AND MATERIALS: Of the 1152 patients who have been treated at Yale-New Haven Hospital before 1990, 136 patients have experienced IBTR as their primary site of failure. These relapses were classified as either NP or TR. Specifically, patients were classified as NP if the recurrence was distinctly different from the primary tumor with respect to the histologic subtype, the recurrence location was in a different location, or if the flow cytometry changed from aneuploid to diploid. This information was determined by a detailed review of each patient's hospital and/or radiotherapy record, mammograms, and pathologic reports. RESULTS: As of 2/99, with a mean follow-up of 14. 2 years, the overall ipsilateral breast relapse-free rate for all 1152 patients was 86% at 10 years. Using the classification scheme outlined above, 60 patient relapses were classified as TR, 70 were classified as NP and 6 were unable to be classified. NP patients had a longer mean time to breast relapse than TR patients (7.3 years vs. 3.7 years, p < 0.0001) and were significantly younger than TR patients (48.9 years vs. 54.5 years, p < 0.01). Patients developed both TR and NP at similar rates until approximately 8 years, when TR rates stabilized but NP rates continued to rise. By 15 years following original diagnosis, the TR rate was 6.8% compared to 13.1% for NP. Of the patients who had been previously tested for BRCA1/2 mutations, 17% (8/52) had deleterious mutations. It is noteworthy that all patients with deleterious mutations had new primary IBTR, while patients without deleterious mutations had both TR and NP (p = 0.06). Ploidy was evenly distributed between TR and NP but NP had a significantly lower S phase fraction (NP 13.1 vs. TR 22.0, p < 0.05). The overall survival following breast relapse was 64% at 10 years and 49% at 15 years. With a mean follow-up of 10.4 years following breast relapse, patients with NP had better 10-year overall survival (TR 55% vs. NP 75%, p < 0.0001), distant disease-free survival (TR 41% vs. NP 85%, p < 0.0001), and cause-specific survival (TR 55% vs. NP 90%, p < 0.0001). CONCLUSION: It appears that a significant portion of patients who experience ipsilateral breast tumor relapse following conservative surgery and radiation therapy have new primary tumors as opposed to true local recurrences. True recurrence and new primary tumor ipsilateral breast tumor relapses have different natural histories, different prognoses, and, in turn, different implications for therapeutic management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050102 · Cited by 1,599
Fisher, B., Anderson, S., Redmond, C. K., Wolmark, N., Wickerham, D. L., & Cronin, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332203 · Cited by 1,465
Jacobson, J. A., Danforth, D. N., Cowan, K. H., d'Angelo, T., Steinberg, S. M., Pierce, L., Lippman, M. E., Lichter, A. S., Glatstein, E., & Okunieff, P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321402 · Cited by 892
Significance of ipsilateral breast tumour recurrence after lumpectomy
Fisher, B., Anderson, S., Fisher, E. R., Redmond, C., Wickerham, D. L., Wolmark, N., Mamounas, E. P., Deutsch, M., & Margolese, R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90475-5 · Cited by 556
Fourquet, A., Campana, F., Zafrani, B., Mosseri, V., Vielh, P., Durand, J.-C., & Vilcoq, J. R. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90057-6 · Cited by 509
Veronesi, U., Marubini, E., Vecchio, M. D., Manzari, A., Andreola, S., Greco, M., Luini, A., Merson, M., Saccozzi, R., Rilke, F., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.1.19 · Cited by 505
Veronesi, U., Banfi, A., Salvadori, B., Luini, A., Saccozzi, R., Zucali, R., Marubini, E., Del Vecchio, M., Boracchi, P., Marchini, S., et al. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90113-8 · Cited by 493
Treatment of early-stage breast cancer
Hurd, T. C., Edge, S. B., Kahlenberg, M. S., Stomper, P. C., Proulx, G. M., Schwartz, G., Khatri, V., & Winston, J. S. (1999) · Current Problems in Cancer · doi:10.1016/s0147-0272(99)90004-1 · Cited by 477
Kurtz, J. M., Amalric, R., Brandone, H., Ayme, Y., Jacquemier, J., Pietra, J.-C., Hans, D., Pollet, J.-F., Bressac, C., & Spitalier, J.-M. (1989) · Cancer · doi:10.1002/1097-0142(19890515)63:10<1912::aid-cncr2820631007>3.0.co;2-y · Cited by 423
Schnitt, S. J., Connolly, J. L., Harris, J. R., Hellman, S., & Cohen, R. B. (1984) · Cancer · doi:10.1002/1097-0142(19840301)53:5<1049::aid-cncr2820530506>3.0.co;2-o · Cited by 354
Cited by
Wapnir, I. L., Anderson, S. J., Mamounas, E. P., Geyer, C. E., Jeong, J.-H., Tan-Chiu, E., Fisher, B., & Wolmark, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3273 · Cited by 466
Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J.-H., Geyer, C. E., Wickerham, D. L., Costantino, J. P., & Wolmark, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8424 · Cited by 458
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Local Therapy and Survival in Breast Cancer
Punglia, R. S., Morrow, M., Winer, E. P., & Harris, J. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065241 · Cited by 317
Blichert-Toft, M., Nielsen, M., Düring, M., Møller, S., Rank, F., Overgaard, M., & Mouridsen, H. T. (2008) · Acta Oncologica · doi:10.1080/02841860801971439 · Cited by 300
Metadata
- Authors
- Smith, T. E., Lee, D., Turner, B. C., Carter, D., & Haffty, B. G.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 48
- Issue
- 5
- Pages
- 1281-1289
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2009224696
- Cited by
- 312
- References
- 21
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: True recurrence vs. new primary ipsilateral breast tumor relapse: An analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. https://app.cochat.ai/papers/10.1016/s0360-3016(00)01378-x
- The paper
- Smith, T. E., Lee, D., Turner, B. C., Carter, D., & Haffty, B. G. (2000). True recurrence vs. new primary ipsilateral breast tumor relapse: An analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/s0360-3016(00)01378-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.